This webinar is brought to you by Connect: Health Tech: www.connect.cam.ac.uk

The profile and importance of the life science sector has never been higher, with the Covid-19 pandemic accelerating drug discovery and novel treatments, and reshaping society’s view and trust of healthcare technologies. The role of AI bespoke methods and network analysis to uncover hidden pathways and reposition drugs for use in treatments is one example of the positive impacts this interdisciplinary convergence of life science and AI/Machine Learning can have on developing the transformative therapies of the future.

Event aims:
The aim of this event is to discuss how AI and machine learning are transforming the clinical pathway from reducing drug discovery timeframes and improving early detection diagnostics, to enabling more efficient clinical trials that benefit patient treatments and outcomes.The panel event will be held online via Zoom to widen participation in the event.

Programme:
1.00pm Welcome and introduction
Dr Namshik Han, Head of Computational Biology and Artificial Intelligence, Milner Therapeutics Institute
1.05pm Embracing new horizons: the landscape for life science and AI/Machine Learning
Prof. Andres Floto, Co-Director, Cambridge Centre for AI in Medicine (CCAIM)
1.10pm Perspectives on the opportunities and challenges in embedding AI and machine learning across the clinical pathway
Dr Ellen McDonagh, Open Targets Informatics Science Director, EMBL-EBI
Joe Day, Business Development Executive (AI/Data), Cancer Research Horizons
1.20pm Case Study - Benefits of AI from a clinical perspective
Dr Kourosh Saeb-Parsy, Honorary Consultant & Transplant Surgeon, Addenbrooke's Hospital, Cambridge
1.30pm Panel Discussion
1.40pm Q&A with attendees
2.00pm Wrap up and Close